Baudax Bio, Inc. BXRXQ

 — 
0.00 0.00 NaN as of 25 Sep
Market cap
—
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Older periods Dec '22 Mar '23 Jun '23 Sep '23
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
0.25 0.31 0.07 0.02
Current Ratio
0.30 0.33 0.09 0.07
Net Debt/EBITDA
(0.05) (0.77) (0.63) (2.96)
Debt/Assets
70.96% 105.21% 27.50% 25.40%
Debt/Equity
(0.29) (1.02) (0.55) (0.51)
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
1.59 (0.35) 0.46 1.23
Capex/Depreciation
(0.01) 0.00 0.00 (0.16)
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.21 0.30 0.60 0.62
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(44.27) (1.70) (0.69) (0.30)
Capex per Share
(0.06) 0.00 0.00 0.00
Free Cash Flow per Share
(44.33) (1.70) (0.69) (0.30)
Cash per Share
15.84 1.64 0.29 0.05
Shareholders Equity per Share
(73.02) (3.15) (2.19) (1.28)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(73.02) (3.15) (2.19) (1.28)
Free Cash Flow
(14.72) (3.94) (3.37) (2.39)
Working Capital
(15.11) (8.26) (18.60) (17.71)
Capital Expenditures
(0.02) — — (0.02)
Net Current Asset Value
(27.93) (10.27) (30.13) (29.48)
EV/EBIT
— — — —
Capex to Sales
0.00 — — 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Other line items
Average Payables
2.33 3.56 4.45 5.72
Average Assets
31.65 27.94 31.08 19.05
Average Common Equity
(5.51) 1.22 (3.22) (14.89)

Fold the line items

Columns are period end dates